2015 Fiscal Year Final Research Report
Developing new therapeutic drugs that inhibit oligomer formation of polyglutamine disease proteins based on the hypothesis of oligomer toxicity in polyglutamine diseases
| Project/Area Number |
25461272
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Onodera Osamu 新潟大学, 脳研究所, 教授 (20303167)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 脊髄小脳変性症 / ポリグルタミン病 / 治療 / 重合体 |
|---|
| Outline of Final Research Achievements |
We developed new therapeutic drugs that inhibit oligomer formation of polyglutamine disease proteins based on the hypothesis of oligomer toxicity in polyglutamine diseases. Using a disease nematode model, we found a small compound that inhibit oligomer formation of disease proteins and ameliorate motor function of the nematode model. We also developed a novel system using iPad for the quantitative assessment of cerebellar ataxia. In addition, we started a clinical trial to investigate the safety and efficiency of varenicline (Champix), a prescription medication used to treat nicotine addiction, in the treatment of spinocerebellar degenerations.
|
| Free Research Field |
医歯薬学
|
